News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,413 Results
Type
Article (87457)
Company Profile (739)
Press Release (770199)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232787)
Career Advice (4144)
Deals (39873)
Drug Delivery (144)
Drug Development (91194)
Employer Resources (205)
FDA (18263)
Job Trends (17422)
News (396897)
Policy (39844)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (122)
Alliances (56796)
ALS (153)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (315)
Approvals (18374)
Artificial intelligence (467)
Autoimmune disease (155)
Automation (31)
Bankruptcy (402)
Best Places to Work (12513)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (146)
Brain cancer (52)
Breast cancer (540)
Cancer (4289)
Cardiovascular disease (306)
Career advice (3569)
Career pathing (41)
CAR-T (289)
CDC (36)
Celiac Disease (1)
Cell therapy (762)
Cervical cancer (29)
Clinical research (76136)
Collaboration (1604)
Company closure (4)
Compensation (990)
Complete response letters (64)
COVID-19 (2928)
CRISPR (85)
C-suite (732)
Cystic fibrosis (144)
Data (5420)
Decentralized trials (2)
Denatured (73)
Depression (116)
Diabetes (346)
Diagnostics (6977)
Digital health (23)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (252)
Drug pricing (162)
Drug shortages (19)
Duchenne muscular dystrophy (198)
Earnings (98021)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132811)
Executive appointments (826)
FDA (20636)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1270)
Gene editing (183)
Generative AI (46)
Gene therapy (602)
GLP-1 (938)
Government (5324)
Grass and pollen (4)
Guidances (279)
Healthcare (20777)
HIV (44)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (272)
Immuno-oncology (58)
Indications (80)
Infectious disease (3150)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (95)
Intellectual property (198)
Interviews (816)
IPO (17808)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (67)
Kidney cancer (16)
Labor market (92)
Layoffs (640)
Leadership (38)
Legal (10091)
Liver cancer (87)
Longevity (13)
Lung cancer (583)
Lymphoma (331)
Machine learning (41)
Management (66)
Manufacturing (715)
MASH (160)
Medical device (14423)
Medtech (14453)
Mergers & acquisitions (22745)
Metabolic disorders (1074)
Multiple sclerosis (150)
NASH (22)
Neurodegenerative disease (327)
Neuropsychiatric disorders (82)
Neuroscience (2897)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5079)
Now hiring (65)
Obesity (527)
Opinion (326)
Ovarian cancer (150)
Pain (155)
Pancreatic cancer (170)
Parkinson's disease (260)
Partnered (35)
Patents (398)
Patient recruitment (415)
Peanut (56)
People (66280)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23599)
Phase 2 (33126)
Phase 3 (24836)
Pipeline (4304)
Policy (284)
Postmarket research (3544)
Preclinical (10587)
Press Release (72)
Prostate cancer (203)
Psychedelics (52)
Radiopharmaceuticals (278)
Rare diseases (799)
Real estate (7422)
Recruiting (80)
Regulatory (28242)
Reports (63)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (65)
Schizophrenia (140)
Series A (225)
Series B (160)
Service/supplier (25)
Sickle cell disease (86)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4325)
State (2)
Stomach cancer (14)
Supply chain (74)
Tariffs (76)
The Weekly (122)
Vaccines (1001)
Venture capital (91)
Weight loss (346)
Women's health (73)
Worklife (22)
Date
Today (21)
Last 7 days (477)
Last 30 days (1956)
Last 365 days (25375)
2026 (2392)
2025 (25628)
2024 (34075)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (85)
Alaska (6)
Arizona (288)
Arkansas (8)
Asia (51122)
Australia (9002)
California (9741)
Canada (2480)
China (1055)
Colorado (307)
Connecticut (390)
Delaware (296)
Europe (116909)
Florida (1262)
Georgia (257)
Hawaii (4)
Idaho (65)
Illinois (657)
India (56)
Indiana (445)
Iowa (21)
Japan (340)
Kansas (133)
Kentucky (25)
Louisiana (14)
Maine (62)
Maryland (1258)
Massachusetts (7315)
Michigan (245)
Minnesota (452)
Mississippi (5)
Missouri (79)
Montana (28)
Nebraska (29)
Nevada (106)
New Hampshire (57)
New Jersey (2561)
New Mexico (29)
New York (2555)
North Carolina (1412)
North Dakota (9)
Northern California (4784)
Ohio (258)
Oklahoma (18)
Oregon (51)
Pennsylvania (1870)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (13)
South Dakota (1)
Southern California (3753)
Tennessee (58)
Texas (1359)
United States (33857)
Utah (209)
Vermont (1)
Virginia (169)
Washington D.C. (54)
Washington State (818)
West Virginia (2)
Wisconsin (82)
858,413 Results for "peak bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
November 10, 2025
·
9 min read
Deals
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Akari Therapeutics, Plc and Peak Bio Inc. announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC platform technology and Akari’s PAS-nomacopan Geographic Atrophy program.
May 1, 2024
·
16 min read
Press Releases
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 5, 2026
·
4 min read
Deals
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics, Plc and Peak Bio Inc. announce a definitive agreement to merge as equals in an all-stock transaction.
March 5, 2024
·
17 min read
Bankruptcy
Biopharma Bankruptcies Still At Peak, With Little Relief in Sight
2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.
February 19, 2025
·
5 min read
·
Annalee Armstrong
Press Releases
Navitas Life Sciences Named a Major Contender in Everest Group Clinical Data Management Operations PEAK Matrix(R) Assessment 2025
October 3, 2025
·
2 min read
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
Regulatory documents show how 89bio’s board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments.
October 2, 2025
·
3 min read
·
Annalee Armstrong
Biotech Bay
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Peak Bio, Inc. (“Peak Bio” or the “Company”) (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office (USPTO).
January 4, 2024
·
7 min read
Press Releases
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
January 27, 2026
·
2 min read
Biotech Bay
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics, Plc and Peak Bio Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction.
March 5, 2024
·
17 min read
1 of 85,842
Next
